|
Originally published In Press as doi:10.1074/jbc.M101812200 on May 11, 2001
J. Biol. Chem., Vol. 276, Issue 31, 29330-29337, August 3, 2001
Specific Pax-6/Microphthalmia Transcription Factor
Interactions Involve Their DNA-binding Domains and Inhibit
Transcriptional Properties of Both Proteins*
Nathalie
Planque,
Laurence
Leconte,
Frédéric M.
Coquelle,
Patrick
Martin, and
Simon
Saule
From the CNRS UMR 146, Institut Curie Section Recherche, Centre
Universitaire Bâtiment 110, 91405 Orsay Cedex, France
Received for publication, February 27, 2001, and in revised form, April 25, 2001
 |
ABSTRACT |
Pax-6 and microphthalmia transcription factor
(Mitf) are required for proper eye development. Pax-6, expressed in
both the neuroretina and pigmented retina, has two DNA-binding domains: the paired domain and the homeodomain. Mice homozygous for Pax-6 mutations are anophthalmic. Mitf, a basic helix-loop-helix leucine zipper (b-HLH-LZ) transcription factor associated with the onset and
maintenance of pigmentation, identifies the retinal pigmented epithelium during eye development. Loss of Mitf function results in the
formation of an ectopic neuroretina at the expense of the dorsal
retinal pigmented epithelium. In the present study, we investigated the
interaction between Pax-6 and Mitf. In transient transfection-expression experiments, we found that transactivating effects of Pax-6 and Mitf on their respective target promoters were
strongly inhibited by co-transfection of both transcription factors.
This repression was due to direct protein/protein interactions involving both Pax-6 DNA-binding domains and the Mitf b-HLH-LZ domain.
These results suggest that Pax-6/Mitf interactions may be critical for
retinal pigmented epithelium development.
 |
INTRODUCTION |
Eye development proceeds from two principal tissue components: the
neural ectoderm, which buds from the forebrain to form the optic
vesicle, and the surface ectoderm, which forms the lens. The optic
vesicle invaginates, producing the optic cup with an inner layer that
forms the neural retina (NR)1
and an outer layer that forms the retinal pigmented epithelium (RPE),
which can be related to melanocytes on the basis of its melanin
content. RPE and NR embryonic cells have a common precursor and share
the characteristic of remaining plastic after they have reached their
terminal differentiation stage. Indeed, cells from the RPE have the
potential to transdifferentiate into lens or neuronal cells (1-4), and
conversely, cells from the NR have the potential to transdifferentiate
into pigmented cells (5). Cell differentiation is the product of
differential gene expression, and transcription factors regulate such events.
Recent progress in the genetics of vertebrate eye development is linked
to the discoveries of genes encoding transcription factors, such as
Pax-6, which is able to initiate an entire cascade of gene activity
sufficient to generate a complete eye (6). Pax-6, a member of the
paired domain family of transcription factors, has a specialized
homeodomain, which is downstream of a DNA-binding paired domain and
upstream of a C-terminal activation domain (7, 8). Pax-6
encodes five proteins through alternative splicing and internal
initiations (9). Three proteins of 48, 46, and 43 kDa contain a paired
domain, but two proteins of 33 and 32 kDa are devoid of this
DNA-binding domain. Pax-6 is known to be critical for eye development
(10). Mutations in the PAX-6 gene cause the aniridia
syndrome in humans (11) and the small eye phenotype in mice (12). Pax-6
is expressed in presumptive eye tissues, and both the semi-dominant
pattern of inheritance of the Pax-6 mutant phenotype (10, 12) and
experimental manipulations using transgenes based on the
Pax-6 locus (13) indicate that achieving the correct level
of Pax-6 is important for development of a normal eye.
Mutation of the microphthalmia-associated transcription factor
(Mitf, a b-HLH-LZ family member) (14) induces the human
Waardenburg syndrome type 2, a hereditary disorder associated with
melanocyte abnormalities (15, 16). This gene is of special interest in relation to the NR and RPE development and transdifferentiation phenomenon because it has been shown to play a critical role in RPE
development. Mutation of Mitf in mi mice results in
microphthalmia associated with an abnormal development of the RPE,
which appears unpigmented and often pluristratified (17-19).
Spontaneous transdifferentiation of quail RPE in vivo is
accompanied by a mutation in this gene (20), suggesting a role for Mitf
in both cellular differentiation and control of cell division. We have
previously found that chicken or quail NR cells expressing Mitf are
responsive to FGF2 and that these cells become rapidly pigmented
in vitro, in contrast to the control cells transfected
with the empty DNA vector (21). Mitf regulates the expression of genes
involved in melanogenesis, including QNR-71, which encodes a
melanosomal protein (5), and several enzyme-encoding genes controlling
the melanin synthesis. These genes include the tyrosinase (22, 23) and
tyrosinase-related peptide 1 (24). All of these genes are regulated by
Mitf through a direct binding at the CATGTG hexameric motif (E-box)
present in their promoter regions (5, 25, 23).
Experiments have shown that Pax-6 can interact with
homeodomain-containing transcription factors (27-29), CBP/p300
co-factors (30), and with members of the tumor suppressor
retinoblastoma protein (pRB) (31). Mitf also interacts with pRB (24)
and CBP/P300 (33). Thus, in view of the importance of both Pax-6 and
Mitf for eye development, and because the two proteins are simultaneously present in the developing RPE, we tested whether they
could interact with each other. This interaction would be of particular
interest for RPE differentiation because Mitf-deficient mice or quails
exhibit spontaneous neuronal transdifferentiation of depigmented RPE
in vivo (20).
The present results showed that both DNA-binding domains of Pax-6
interact with the b-HLH-LZ domain of Mitf. This interaction strongly
reduces transactivation of Pax-6 as well as Mitf-responsive promoters.
No inhibition is observed with the mi mutant form of Mitf. Based
on these data, we consider that Pax-6 and Mitf interaction may be
required for normal retinal pigmented epithelium differentiation in vivo.
 |
EXPERIMENTAL PROCEDURES |
Mitf and Pax-6 Constructs--
The pSFCV-LE-Mi (see Ref. 21) was
digested with EcoRI to produce construct pSG5-Mitf (amino
acids 1-413). pCRII-Mitf-(193-413) (see Ref. 21) was digested
with BamHI to produce construct pSG5-Mitf-(193-413) using a
modified pSG5 including an AUG upstream of the BamHI site. The pSG5-Mitf-(1-413) plasmid was digested with
PstI/SpeI, blunt-ended with mung bean nuclease,
and ligated to produce construct pSG5-Mitf-(1-318). pSG5-Mitf-(193-413) was digested with AgeI/SpeI,
end-filled with Klenow, and ligated to make construct
pSG5-Mitf-(193-297). pSG5-Mitf was digested with XbaI. The
resulting vector was then digested with
SpeI/BamHI, blunt-ended with mung bean nuclease,
and ligated to obtain pSG5-Mitf-(1-140). pSG5-Mitf-(193-413) was
digested with SpeI/XhoI, end-filled with Klenow,
and ligated. The resulting plasmid was then digested with
BamHI/AgeI, end-filled with Klenow, and
ligated, giving construct pSG5-Mitf-(297-413). The pEF-BOS-Mitf wild type and mi mutant constructs have been described
previously (34) and were kindly provided by Dr. S. Nomura. A Mitf
cDNA fragment corresponding to the full-length protein was
amplified by polymerase chain reaction using oligonucleotides 5'-CAC
GAA TTC CAT GCT GGA AAT GCT AGA A-3' (position +45) and 5'-TGT GCG GCC
GCC TAA CAC GCA TGC TCC GT-3' (position +1270). The amplification product was cloned in pCRII and sequenced. The Mitf cDNA was
then inserted between the EcoRI-NotI sites of
pGEX-4T3. pCRII-Mitf-(193-413) was digested with EcoRI and
cloned in the EcoRI site of pGEX-1 T. These two
subclonings resulted in the in-frame fusion of the desired sequence to
the GST protein.
pSG5-p46* encodes a Pax-6 p46 isoform containing three point mutations
in the paired domain (S93A, F95N, and E98Q). To generate this mutant,
we used the Chameleon double-stranded site-directed mutagenesis kit
(Stratagen) using pSG5-p46 (8) as a template and oligonucleotide 5'-CGA
GAG TGC CCC GCC ATC AAT GCG TGG CAG ATT CGA GAC-3'.
PAX-3-encoding vector pSRa MSV/PAX-3 was kindly provided by Dr.
M. F. Roussel (35).
Cell Cultures, Transfections, and Luciferase and CAT
Assays--
Baby hamster kidney (BHK)-21 cells were cultured in 10%
fetal calf serum in Dulbecco's modified Eagle's medium.
Dissociated RPE dissected from 8-day-old quail embryos was plated in
Dulbecco's modified Eagle's medium/F-12 containing 10% fetal calf
serum, 1% vitamins, 100× minimum Eagle's medium, and 10 µg/ml
conalbumin. Cells were seeded 24 h prior to transfection as
described previously (36). BHK21 cell transfections were performed with
PEI reagent (Exgen 500, Euromedex, Souffelweyersheim) according
to the instructions of the manufacturer. Varying amounts of expression
plasmid were co-transfected as indicated in the respective figures. The
total amount of transfected DNA was kept constant by adding empty
expression vector DNA. Tyrosinase promoter was a pGL2 vector (pMT2.2,
kindly provided by Dr. R. Ballotti (37)). Details on QNR-71 has
been published previously (5) as well as the G3-138 glucagon promoter (28). A RSV-LacZ or a pcDNA3-LacZ vector was co-transfected for normalization of luciferase and CAT assays by controlling the
-galactosidase activity. RPE cells transfections were performed by
the calcium phosphate method. After transfection (48 h), cells were
harvested and lysed in reporter lysis buffer (Promega). Luciferase and
CAT assays were performed as described previously (36). The levels of
CAT activity were quantified after exposure of the thin-layer
chromatograms to a PhosphorImager screen.
In Vitro Translation and Glutathione S-transferase (GST)
Pull-down Assays--
The 35S-radiolabeled proteins were
translated in vitro using the TNT system (Promega). The GST
chimerical proteins were extracted from bacteria following the
manufacturer's instructions (Amersham Pharmacia Biotech). Labeled
proteins were pre-incubated with empty glutathione-Sepharose beads for
30 min at 4 °C. GST proteins on glutathione-Sepharose beads were
pre-incubated with 40 µg of bovine serum albumin. Bead volumes were
kept constant by adding empty beads. The pull-down assays were
performed in 25 mM Hepes, pH 7.5, 150 mM KCl,
12.5 mM MgCl2, 0.1% Nonidet P-40, and 20%
glycerol. Proteins were incubated for 1 h at 4 °C, and then the
beads were washed four times in 20 mM Tris-HCl, pH 8, 100 mM NaCl, 1 mM EDTA, and 0.5% Nonidet P-40.
Bound proteins were eluted by boiling and analyzed on
SDS-polyacrylamide gel electrophoresis. The gel was treated with 16%
natrium salicylate to amplify signals and dried before exposure to a
phosphorimaging screen.
Electrophoretic Mobility Shift Assay--
The DNA probe used was
the P6CON double-stranded oligonucleotide (5'-GGA TGC AAT TTC ACG CAT
GAG TGC CTC GAG GGA TC-3') [ -32P]ATP-labeled with the
PolyNucleotide kinase T4. G1-51 (5'-CAA AAC CCC ATT ATT TAC AGA TGA
GAA ATT TAT ATT GTC AGC GTA ATA TCT-3') is a wild type glucagon
promoter element that has been shown to bind Pax-6 (28). Gel
retardation assays were performed as described previously (36) with 50 ng of bacterially expressed proteins.
Immunocytochemistry--
Transfected cells cultured on 16-mm
microscope coverslips were fixed for 1 h with 2%
paraformaldehyde in PBS and then treated with serum MiC (see
21). Anti-Mi-reactive proteins were detected with CY3-labeled goat
anti-rabbit immunoglobulin secondary reagent (Jackson ImmunoResearch).
EGFP and DsRed Fusion Protein Constructs--
To visualize both
Pax-6 and Mitf proteins, enhanced green fluorescent protein (EGFP,
CLONTECH) and Discosoma striata
red protein (DsRed, CLONTECH) were used as
fusion partners of p46 and Mitf, respectively. The following plasmids
were constructed: a BglII-NotI EGFP fragment was
ligated to the BglII and Bsp120I sites of pVNC3 (modified from pVM116 (38)) to produce pVNC3EGFP. A
BamHI-Bsp120I Pax-6 fragment was inserted into
the NotI and BglII sites of pVNC3EGFP to make
pVNC3Pax6-EGFP, which was then digested by HindIII and BamHI and Klenow-treated, giving pVNC3Pax6EGFP. A
BglII-NotI DsRed fragment was ligated to the
BamHI and Bsp120I sites of pVNC3 producing pVNC3Red. A HindIII-SalI fragment encompassing
the whole Mitf coding region was inserted in the
HindIII-SalI sites of pVNC3Red to produce pVNC3
MiRed. An EGFP-myc fusion was used as a negative control. An
EcoRI-Bsp1407 Klenow-treated EGFP fragment (from
pEGFP-1, CLONTECH) was ligated to an
EcoRV-SphI Klenow-treated v-Myc fragment (from
MC29) and inserted into the EcoRI and BglII
Klenow-treated sites of pVNC7 (which is the pVNC3 plasmid with an
inverted multiple cloning site) to produce pVNC7EGFPmyc. pVNC3MiRed was
co-transfected with either pVNC3Pax6EGFP or pVNC7EGFPmyc into E8 quail
retinal pigmented cells. To determine the two chimera
localization, cells were fixed for 20 min at room temperature in
3% paraformaldehyde in PHEM buffer (60 mM Pipes, 25 mM Hepes, 10 mM EGTA, 1 mM
magnesium acetate, pH 6.9). Cells were washed three times in PBS and
permeabilized for 25 min in 0.1% Triton X-100 in PBS. Chromosomes were
stained with 4',6-diamidino-2-phenylindole (DAPI, Sigma) for 5 min. After a rinse in PBS, coverslips were mounted in 50% PBS-glycerol
containing anti-fading reagent 1.4 diazabicyclo-(2-2-2)octane (DABCO,
Sigma) at 100 mg/ml.
Wide Field Optical Sectioning Fluorescence
Microscopy--
Pictures of fixed cells were collected using a
three-dimensional deconvolution imaging system, the detailed
description and validation of which will be published
elsewhere.2 Briefly, it
consisted of a Leica DM RXA microscope equipped with a piezoelectric
translator (PIFOC, Physik Instruments, Waldbronn, Germany)
placed at the base of a 100× PlanApo N.A. 1.4 objective, and a 5-MHz
Micromax 1300Y interline CCD (charge-coupled device) camera (Roper
Instruments, France). For the acquisition of Z-series, the camera was
operated at full speed and controlled the Piezo translator at the start
of each CCD chip read-out. Stacks containing fluorescence images were
collected automatically at 0.2 µm Z-intervals (Metamorph software,
Universal Imaging). Wavelength selection was achieved by switching to
the corresponding motorized selective Leica filter block before each
stack acquisition. Tests using 50-nm Tetraspec beads (Molecular Probes)
showed that the system did not generate x-y pixel shifts, and that
Z-plane shifts between colors, due to chromatic aberrations, were
reproducible and could be corrected for. Exposure times were adjusted
to provide ~3000 gray levels at sites of strong labeling. Automated
batch deconvolution of each Z-series was computed using a measured
point spread function and constrained iterative deconvolution with a
custom-made software package. The point spread function of the optical
system was extracted from three-dimensional images of fluorescent beads
0.1 µm in diameter (Molecular Probes) collected at each wavelength.
The Z-series were pseudocolored and overlaid, and maximal pixel
intensity projections were calculated with the help of Metamorph software (Universal Imaging).
 |
RESULTS |
Pax-6 Interacts with Mitf--
To test the hypothesis that Pax-6
interacts physically with Mitf, we prepared affinity columns consisting
of glutathione-Sepharose coupled with a GST Paired fusion protein
containing the paired domain from the p46 (GSTPrd46, amino acids
3-131) or the p48 (GSTPrd48, amino acids 3-145) and GST-Hom,
containing the p46 homeodomain (amino acids 224-284), GST-Prd46-Hom
(amino acids 3-270) and GST-p46 containing the full-length Pax-6
product. We also used GST as a negative control. In vitro
radiolabeled Mitf protein was loaded onto these columns and washed, and
bound proteins were eluted by boiling and analyzed on
SDS-polyacrylamide gel electrophoresis. The percentage of bound
radioactivity was calculated using a PhosphorImager. A comparable
amount of radiolabeled Mitf was recovered on GST-Paired (1.7% of the
input, Fig. 1, lane 3) and
GST-Hom (3.7% of the input, Fig. 1, lane 4). These results
indicated that Mitf associated directly with both the paired and
homeodomains of Pax-6. Similar results were obtained with the p48
paired domain (0.75% of the input; Fig. 1, lane 2),
suggesting that both Pax-6 isoforms interacted with Mitf. In addition,
we observed a more efficient binding to Mitf using the
GST-Prd46-Hom (4.6%) than with the paired or homeodomain alone,
suggesting that Mitf interacted simultaneously with both of these
DNA-binding domains (Fig. 1, compare lanes 3, 4,
and 5). Stronger retention was not observed with the
full-length p46 (3.9%), indicating that the p46 C terminus is not a
Mitf-interacting domain (Fig. 1, lane 6).

View larger version (41K):
[in this window]
[in a new window]
|
Fig. 1.
Both the Pax6 paired
domain and homeodomain interact with Mitf. The
35S-labeled full-length Mitf protein was translated
in vitro and incubated with GST-Pax6 proteins. The GST
protein showed no interaction with the translated Mitf protein
(lane 1). Mitf interacted with paired domains of p46 or p48
(lanes 2 and 3) as well as p46 homeodomain
(lane 4). Stronger interaction was observed when both
domains were present (lane 5) or with the full-length
protein (lane 6).
|
|
To identify the regions in Mitf required for physical interaction with
the Pax-6 p46, we carried out in vitro binding experiments by using various deletion mutants of Mitf (Fig.
2A). As shown in Fig.
2B, both the N terminus of the protein (amino acids 1-140, lane 5) and the b-HLH-LZ domains (193-297, lane
4) were able to bind to GST-p46 with weak and strong affinities,
respectively. The C terminus of Mitf (amino acids 298-413, lane
6) was unable to bind, whereas similar amounts of the truncated
proteins were synthesized in the reticulocyte lysate (Fig.
2C, lane 6). Binding results obtained with the
GST-p46 (Fig. 2B) were also observed with GST-Paired and
GST-Hom (data not shown), indicating that the b-HLH-LZ domain of Mitf
interacts with both of the Pax-6 DNA-binding domains.

View larger version (40K):
[in this window]
[in a new window]
|
Fig. 2.
Mitf b-HLH-LZ domain is required for
interaction with Pax6. A, schematic representation of
the Mitf constructs used for in vitro translation and the
GST pull-down assay. Lane 1 shows the full-length Mitf
protein of 413 amino acids with its b-HLH-LZ domain. Lanes
2-6 represent various Mitf deletion constructs used in this
study. The numbers refer to amino acids. B,
autoradiograph of the GST pull-down assay (overnight exposure).
35S-Labeled Mitf proteins were translated in
vitro and incubated with truncated GST-p46 proteins. The strongest
Pax6/Mitf interaction was observed when the b-HLH-LZ domain was
included (lanes 1-4). A faint interaction was seen with the
N-terminal part of Mitf protein (amino acids 1-140)
(lane 5). No interaction was detected with the C-terminal
part of Mitf-(298-413) (lane 6). C,
autoradiograph of the inputs exposed for 2 h.
|
|
Mitf Recognizes the p46 Paired Domain through the C-terminal
Subdomain and Can Inhibit the DNA Binding Activity of Pax-6--
It
has been shown that the Pax-5 paired domain can recruit Ets DNA-binding
domains to the Pax-5 C-terminal subdomain DNA-binding site to form
ternary complexes on a B-cell-specific promoter (39). The structure and
docking of Pax-5 should be nearly identical to Pax-6, because their
C-terminal subdomains are 75% identical and all DNA-contacting
residues are conserved (40). Modeling the C-terminal subdomain of
paired with the Max b-HLH shows that residues of the second
helix of the paired C-terminal subdomain (Ser-93, Phe-95, and Glu-98;
see Fig. 5A) can pack against the loop of Max HLH and
interact with the Asp-236, Asp-238, and Arg-240 (equivalent
amino acids in Mitf). To test the possibility that these residues are
involved in the Pax-6/Mitf interaction, we replaced by directed
mutagenesis S93A, F95N, and E98Q in the p46 protein and D236N, D238N,
and R240N in the Mitf protein. Wild type Pax-6 (Fig.
3 lane 5) or mutagenized Pax-6
proteins (Fig. 3, lane 6) synthesized in vitro,
were loaded onto GST columns. The percentage of bound radioactivity was
calculated using a PhosphorImager. 23% (Fig. 3, lane 3) of
the wild type p46 Pax-6 protein recognized the GST-Mitf-(193-413), but
only a 3% residual binding (Fig. 3 lane 4) was detected
using the mutagenized p46 (p46*) protein. This residual binding could
be observed because of the presence of the homeodomain in the p46*,
since this DNA-binding domain can also bind the Mitf protein (Fig. 1).
However, the paired-less proteins (p32-33) synthesized in
vitro (Fig. 3, lane 5) were not recognized by Mitf
protein (Fig. 3, lanes 3 and 4, compare with lanes 5 and 6). However, no difference was observed in the
amount of radiolabeled Mitf protein recovered on the GST-Prd46 column between the wild type (12.5% of the input) or the Mitf triple mutant
(D236N,D238N,R240N, 12.8% of the input) showing that the modifications introduced into the loop of the HLH domain still allow
protein/protein interaction with Pax-6 (data not shown).

View larger version (49K):
[in this window]
[in a new window]
|
Fig. 3.
Mutations in the p46 paired domain result in
weak Pax6/Mitf interaction. Autoradiograph of the GST pull-down
assay. 35S-labeled wild type p46 or mutated p46* were
translated in vitro and incubated with GST alone or
GST-Mitf-(193-413). Note that the paired-less p32/33 proteins were not
recognized. Lane 3, 23% retention; lane 4, 3%
as calculated from PhosphorImager exposure.
|
|
Because Mitf and Pax-6 interacted through the paired domain, we tested
whether Mitf binding to the p46 protein was able to modulate the DNA
binding activity of this Pax-6 product by using the p46 ability to bind
an oligonucleotide bearing a high affinity paired binding site named
Pax6CON (41). As shown in Fig.
4A, when GST-Mitf-(193-413)
or GST-Mitf-(1-413) proteins were co-incubated with GSTPrd46, a marked
decrease in binding to Pax6CON oligonucleotide was observed (Fig.
4A, compare lane 2 with lanes 3 and
4). However, because the Pax6CON binding site was not a real
binding site present in a Pax-6 target promoter, we performed a similar
experiment using an oligonucleotide containing the Pax-6 binding site
of the G1 element present in the glucagon promoter. As for the Pax6CON, co-incubation with GST-Mitf-(193-413), which is unable to bind this
probe (lane 3), reduced significantly the Pax-6 binding on this oligonucleotide (Fig. 4B, lane 4).

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 4.
Mitf inhibits Pax6 DNA-binding on its
specific gene target. A, electrophoretic mobility shift
assay using a specific p46 oligonucleotide radioactive probe P6CON and
GST-Prdp46, GST-Mitf-(1-413), or GST-Mitf-(193-413). Lane
1, GST protein alone was used as a negative control. Lane
2, P6CON forms a DNA-protein complex with the p46 paired domain.
Lane 3, formation of this complex was inhibited by the
addition of GST-Mitf-(193-413) or GST-full-length Mitf (lane
4). Mitf-(193-413) or full-length Mitf do not bind the DNA probe
(lanes 5 and 6). B, electrophoretic
mobility shift assay using a G1-51 glucagon-derived Pax-6-binding site
radioactive probe and GST-Prdp46 or GST-Mitf-(193-413). Lane
1, GST protein alone was used as a negative control. Lane
2, G1-51 forms a DNA-protein complex with the p46 paired domain.
Mitf-(193-413) do not bind this DNA probe (lane 3).
Lane 4, formation of the paired domain-DNA complex was
inhibited by the addition of GST-Mitf-(193-413).
|
|
Effects of Pax-6/Mitf Protein Interaction on Their Transactivating
Properties--
The Mitf factor is essential for melanocyte
differentiation and is able to activate the promoter of several genes
involved in melanogenesis (5, 14, 22, 24, 42). We tested for whether
the Pax-6/Mitf interaction observed was able to regulate Mitf-dependent QNR-71 and tyrosinase promoter
expression (Fig. 5B). The
QNR-71 promoter (pP 71-220; 0.2 µg) or tyrosinase
constructs (1 µg) were co-transfected into RPE cells with the vector
expressing the murine Mitf protein and increasing amounts of the
pSG5-Pax-6 vector expressing either the p46 or the p48 isoforms (Fig.
5A). Cell lysates were collected 2 days after transfection,
and the levels of CAT and luciferase activities present in the lysates were determined. Co-transfection of the pP 71-220 with the vector expressing the murine Mitf protein resulted in an 8-fold increase of
CAT activity relative to the vector control. A strong increase in
luciferase activity (40-fold) was also observed with the tyrosinase promoter in response to the Mitf protein expression (Fig.
5C). Co-transfection of the Mitf-responsive promoters with
the vectors expressing the Pax-6 isoforms alone (Fig. 5A)
did not modify their activity level relative to the control
vector (Fig. 5C). Co-transfection of either
QNR-71 or tyrosinase promoter with the vectors expressing the Mitf and p46 Pax-6 proteins resulted in an 80-90% reduction of
the Mitf transactivational effect in a dose-dependent
manner (Fig. 5C). Similar results were obtained with the p48
isoform (Fig. 5C). This Pax-6 inhibition was specific to
Mitf transcription factor, because no repression was observed on the
4xGal4 thymidine kinase promoter activated by the Gal4VP16 protein
co-transfected with the p46 encoding vector (data not shown).

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 5.
Co-expression of Pax-6 and Mitf inhibits
their transactivation effects on their target promoters.
A, representation of two Pax-6 isoforms used in this study,
namely p46 and p48. Both isoforms contain two DNA-binding domains: the
paired box and the homeodomain. p48 contains an additional 42-base pair
exon (4A) located in the paired domain. The numbers
refer to amino acids. B, reporter gene promoter constructs
used in the transfection assays. DNA-binding sites for Mitf
(mi) or Pax6 are indicated in the promoters, which drive
either luciferase (Luc) or CAT gene expression.
C, tyrosinase and QNR-71 promoter transactivation
assays. E8 quail RPE cells were transiently transfected with 1 µg of
pMT2.2 (pGL2tyrosinase) or 200 ng of pP 71-220. The total amount of
transfected DNA was kept constant by adding pSG5 empty vector to the
reaction. D, tyrosinase and glucagon promoter
transactivation assays. BHK21 cells were transiently transfected with
500 ng of pMT2.2 (pGL2tyrosinase) and 200 ng of pG3-138 (pBLCAT3
glucagon). The results were normalized to -galactosidase activity
derived from a co-transfected pcDNA3-LacZ expression plasmid.
E, effect of paired domain mutations in Pax-6/Mitf
interactions. 50 ng of pSG5-Mitf was transiently co-transfected into
BHK21 cells with 1 µg of a plasmid encoding either the wild type Pax6
(pSG5-p46) or the p46* mutated in the paired domain and 200 ng of a CAT
reporter glucagon promoter construct (pG3-138). CAT activities were
expressed relative to the value for the pG3-138 with the empty vector
(set at a value of 1). Thin lines indicate standard
deviations calculated from transfections performed in duplicate. The
mutant p46* is as efficient as the wild type p46, but its
transactivation effect on the glucagon promoter is only marginally
repressed by Mitf. F, co-expression of PAX-3 and Mitf
inhibits their transactivation effects on QNR-71 promoter.
BHK21 cells were transiently transfected with 10 ng of pP 71-220 and
100 ng of pSG5-Mitf and 500 ng or 1 µg of PAX3-encoding vector pSR
MSV/PAX-3. The total amount of transfected DNA was kept constant by
adding pSG5 empty vector to the reaction.
|
|
Because the Pax-6 proteins were able to repress Mitf activity, we
investigated whether Mitf was able to repress the Pax-6 transactivating
properties. For that purpose, we used as a target the glucagon promoter
linked to the CAT gene, which is strongly activated by the p46 protein
(28). To demonstrate that in the same cells we could obtain both
positive and negative effects on transcriptional regulation, we
introduced the tyrosinase promoter linked to the luciferase reporter
gene (activated by Mitf) together with the glucagon promoter linked to
the CAT gene (activated by Pax-6). Luciferase and CAT activities
present in the lysates were determined, and both were found to have
decreased strongly when compared with the activities obtained with
Pax-6 or Mitf transcription factor alone (Fig. 5D). No
effect of Mitf or Pax-6 (alone or together) was observed on the
-galactosidase activity of a cytomegalovirus promoter included as a
control in the experiment. When we used instead in this assay the p46*
(which interacted poorly with Mitf, Fig. 3), this protein activated the
glucagon promoter as efficiently as the wild type protein but was
2-fold less repressed by Mitf (Fig. 5E). This result
confirms that the C terminus of the paired domain is an important
domain of interaction between the two proteins.
Because Pax-3, a Pax family member expressed in the neural
crest-derived melanocytes, activated the Mitf promoter (43, 44), we
tested whether PAX-3 was able to repress Mitf activity. As shown in
Fig. 5F, PAX-3 was able to reduce Mitf activity on the QNR-71 promoter but to a lesser extend than Pax-6.
Next we asked whether a mutation abrogating the Mitf activity
(deletion of one amino acid in the DNA-binding domain (34)) and
resulting in transdifferentiation of dorsal retinal pigment epithelium
into neural retina (19) could have any effect on Pax-6 transactivation.
This was indeed the case, as shown in Fig. 6. The mutant (Fig. 6C) and
wild type proteins (Fig. 6B) were expressed with a similar
efficiency, but only the wild type protein inhibited the Pax-6
transactivating properties (Fig. 6A).

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 6.
Effect of a mutation in the Mitf basic domain
on Pax6/Mitf interaction. The mi mutation is a 3-base
pair deletion that removes one of the three arginines at the C terminus
of the Mitf basic region. A, constructs expressing either
the wild type (pEF-BOS-Mitf wild type) or the mutated Mitf (pEF-BOS-mi)
were transiently co-transfected into BHK21 cells with a plasmid
encoding Pax-6 (pSG5-p46) and a CAT reporter glucagon promoter
construct (pG3-138). CAT activities were expressed relative to the
value for the pG3-138 with the empty vector (set at a value of
1). Thin lines indicate standard deviations
calculated from transfections performed in duplicate. Wild type Mitf
repressed transactivation of the glucagon promoter by wild type p46,
whereas the mutated allele mi had no inhibitory effect on p46
transactivation. B, Mitf immunodetection on BHK21 cells
transfected with a plasmid expressing the wild type Mitf protein
(pEF-BOS-Mitf). C, Mitf immunodetection on BHK21 cells
transfected with a vector expressing the mutated Mi protein
(pEF-BOS-mi).
|
|
Parts of Pax-6 and Mitf Co-localize in the Nucleus--
To
demonstrate that Pax-6 and Mitf are able to interact in
vivo, we co-transfected vectors expressing p46, tagged with the enhanced green fluorescent protein (EGFP), and Mitf, tagged with the
DsRed protein. Expression of these vectors into E8 quail RPE cells
allowed detection of both proteins in cell nuclei (Fig. 7, A and B). Fig.
7C shows the overlap of the two fluorescent proteins by
maximal pixel intensity projections of a representative nucleus. If a
portion of the protein was localized in distinct parts of the
nucleus, a significant amount of the yellow labeling could
be observed suggesting that, in vivo, p46 and Mitf proteins can co-localize in the nucleus. To demonstrate that such a
co-localization is not an artifact due to a random effect, we performed
a similar co-transfection experiment with a v-Myc protein (which has
been shown not to interact with Mitf in vitro (42)) tagged
with GFP and Mitf tagged with DsRed. In contrast to Pax-6 and Mitf, the overlap of the two fluorescent proteins revealed that Mitf and v-Myc do not substantially co-localize (Fig.
7F).

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 7.
Expression of Pax-6-EGFP and
Mitf-DsRed fusion proteins in RPE cells shows co-localization in
nuclei. Pax-6-EGFP and Mitf-DsRed fusion proteins were transfected
into quail retinal pigmented cells, and the subcellular localization of
the fusion proteins was determined by three-dimensional fluorescence
microscopy of fixed cells. A, Pax-6-EGFP expression in cell
nuclei. B, Mitf-DsRed expression in cell nuclei.
C, overlay of these two expression patterns (A
and B) showing co-localization of Pax-6-EGFP and Mitf-DsRed
fusion proteins in the cell nuclei (see yellow spots). As a
control we determined the subcellular localization of v-Myc and
Mitf. D, EGFP-myc expression in cell nuclei. E,
Mitf-DsRed expression in cell nuclei. F, overlay of these
two expression patterns (D and E) showing no
co-localization of EGFP-myc and Mitf-DsRed fusion proteins in the cell
nuclei (compare with panel C).
|
|
 |
DISCUSSION |
This study provided evidence that Pax-6 interacts with the Mitf
transcription factor and that this interaction suppresses the function
of these molecules as transactivators. Furthermore, we observed that
this interaction involved their respective DNA-binding domains. Because
Pax-6 and Mitf form a protein-protein complex, they are no longer able
to bind DNA and to transactivate their target promoters. We then
investigated which regions of Pax-6 and Mitf DNA-binding domains may be
required for their interaction. The paired domain of Pax-6 can be
divided into two DNA-binding subdomains (45): the N-terminal domain
(PAI) and the C-terminal domain (RED). Several data indicate that
Pax-6/Mitf interactions imply the C terminus of the p46 paired
domain. First, the p46 and p48 paired domains differ only in their N
terminus (45) and are both efficient in Mitf binding and
trans-inhibition. In addition, specific mutagenesis of 3 amino acids in
the C terminus (Ser-93, Phe-95, and Glu-98; see Fig. 5A) of
the p46 paired domain strongly reduced both the interaction with and
the repression by Mitf of a Pax-6-responsive promoter. Interestingly,
Pax-3 repressed Mitf activity to a lesser extend than Pax-6. Close
examination of the Pax-3 paired domain reveals that if Phe-95 and
Glu-98 are conserved in the paired domains of both proteins, Ser-93 of
Pax-6 corresponds to a Gly in Pax-3 (46). Therefore, this amino acid may be important for protein interaction with Mitf. In contrast to the
homeodomain alone (Fig. 1, lane 4), the paired-less proteins (p32-33) synthesized in vitro (Fig. 3, compare lanes
5 and 3) were not recognized by the Mitf protein. That
the paired domain may be able to modulate the function of the
homeodomain intramolecularly (47) explains why the Mitf protein may
bind the homeodomain in the context of p46, explaining the residual
interaction observed with the p46* containing the mutagenized paired
domain (Fig. 3, lane 4). Indeed, it has been shown recently
that C-terminal amino acid 422 is also critical for the DNA binding
activity of the homeodomain in the p46 protein (48). These data suggest
that folding of the homeodomain is controlled by both the N and C
termini of the p46. Therefore, the folding of the homeodomain in
paired-less p32-33 proteins may be different from that of the p46.
However, it remains to be formally demonstrated that the homeodomain in the p46 binds Mitf. Such an inhibitory interaction has already been
observed between paired domain transcription factors of the Pax-2/5/8
subfamily with a HLH Id protein (49). This binding occurred
through the paired domain and resulted in the disruption of DNA-bound
complexes. Thus, the HLH Id protein dissociated the complex formed
between the Ets family member Elk1 and Pax-2/5/8 proteins (49). As for
Mitf, the paired C terminus was involved in the interaction between
Pax-5 and Ets family members (40). Amino acids involved in this
interaction (Trp-97, Arg-100, and Val-117) are very close to those
involved in the interaction between Pax-6 and Mitf, suggesting that the
HLH Id protein may dissociate the Pax-5/Elk1 complex by directly
competing for the same protein/protein interaction domain.
In contrast to the inhibitory effect of the Pax-6/Mitf interaction,
activatory interactions between homeodomain-containing factors and
b-HLH proteins have already been reported (50-52). The presence of
many other factors and co-factors in a cell nucleus in vivo
may influence the DNA-binding and transactivation properties of these
proteins. In this respect, it is interesting to note that the p300
co-factor, which is coupled to the basal transcription machinery, is
able to bind both Pax-6 and Mitf. This interaction enhances the
synergistic effect of Pax-6 and homeodomain-containing protein cdx2 on
the glucagon promoter (30). Such a factor could modulate the
interaction between Pax-6 and Mitf and dictate the inhibitory or
activatory nature of the interaction. Inhibition of Pax-6 DNA binding
is not restricted only to Mitf, because we previously reported that
homeodomain containing Engrailed 1 and 2 factors inhibited Pax-6 DNA
binding and transactivation (27).
What could be the consequence of the inhibitory interaction between
Pax-6 and Mitf for eye development? It is well established that the
division of the optic neuroepithelium into two domains, the presumptive
neuroretina and the pigmented retina, is critical for the development
of the vertebrate eye. The notion that the early optic epithelium is
bipotential may be reflected by the fact that distinct transcription
factors that are later important separately for NR or RPE are initially
coexpressed. For example, in cultured optic vesicles, Mitf expression
was restricted to the RPE layer, whereas Pax-6 staining was found in
both RPE and NR (53). Implantation of FGF1-coated beads resulted in
down-regulation of Mitf and up-regulation of Pax-6 and Chx10. Then RPE
thickened and differentiated along the neuroretinal pathway (53),
suggesting that Mitf down-regulation is required to initiate neuronal
differentiation. Introduction of Mitf-expressing vectors into the avian
neuroretina in vitro induced the differentiation of
pigmented cells in the culture (21) showing that Mitf is dominant over
neuroretinal factors to induce a pigmented phenotype. Consistent with
these observations, when a functional Mitf was missing in
vivo, as in mi/mi mice, the RPE (at least its dorsal
part) lost the expression of RPE-specific genes, thickened, and then
became a laminated second neuroretina (19). Therefore, if we expect the
Pax-6/Mitf interaction to be a critical event in RPE differentiation,
the mutant Mi protein should abolish such an interaction. This mutant (34) lacks an arginine in the basic region of the nuclear localization signal, resulting in a cytoplasmic misrouting of an important part of
the protein and lack of DNA-binding capability. In cotransfection experiments with both Pax-6 and mi coding vectors, we detected a substantial part of the Mi protein in the nucleus of the transfected cells, but we noticed a complete lack of Pax-6 inhibition. In vitro pull-down experiments performed with the Mi protein
translated in a reticulocyte lysate revealed a 33% interaction with
the p46 protein when compared with Mitf set at 100%, suggesting that
the basic domain of Mitf is indeed critical (directly or indirectly) for the interaction with Pax-6 (data not shown). That Pax-6, activated by the lack of interaction with mi mutant, is involved in
the neuronal transdifferentiation of the RPE remains to be
demonstrated. Several lines of evidence suggest a direct involvement of
Pax-6 in neuronal differentiation of the retina. First, mice lacking Pax-6 function do not develop retina (12). In accordance with this
finding, it has been shown that in zebrafish with an experimentally reduced number of Pax-6-expressing cells in the optic vesicle, retinal
differentiation is restricted to cells that retain the Pax-6 protein
(54). Pax-6 ectopic expression in cells nonspecified to generate
neurons, both in invertebrates and vertebrates, is able to specify
retinal identity (6, 10). Finally, introduction of the Pax-6 coding
vector into the cultured RPE cells, in contrast to the empty control
vector, induced expression of HuD into the culture (data not shown).
HuD is an RNA-binding protein specifically expressed in neurons.
Mis-expression of HuD in cultured neural crest cells results in a
dramatic increase in the proportion of cells exhibiting neuronal
morphology, neuronal markers, and neurotrophin dependence (26). Thus,
Pax-6 is able to induce expression of a neuronal marker into RPE cells.
Pax-6 may therefore play a role in the in vivo neuronal
transdifferentiation of RPE cells observed in the mi mutant,
where an inhibitory interaction with Mitf is no longer possible.
Another Pax family member, Pax2, is expressed in the ventral optic
vesicle, later being confined to the proximal region destined to
contribute to the optic nerve. Pax2 null mutant mice show an extension
of the RPE into the optic stalk and failure of the optic fissure to
close (32). As for Pax-6, Mitf suppressed the Pax2 transactivating
function (data not shown), suggesting that one function of Pax2 may be
at least to restrict Mitf activity in the optic stalk area. Therefore,
direct interaction of Pax family members with Mitf may be a general rule.
 |
ACKNOWLEDGEMENTS |
We thank Drs. R. Wintjens and E. Buisine from
the NMR group (UMR 8525, Institut de Biologie de Lille) for
help in designing the Pax-6 and Mitf mutations. We thank Neda Zahedi
for comments on the manuscript.
 |
FOOTNOTES |
*
This work was supported by grants from the Centre National
de la Recherche Scientifique, the Institut Curie, the Association Retina France, the Association pour la Recherche contre le Cancer, the
Ligue Nationale contre le Cancer, the Fondation pour la Recherche Médicale, and the Association de Secours des Amis des Sciences.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed. Tel.:
33-1 69 86 71 53; Fax: 33-1 69 07 45 25; E-mail:
Simon.Saule@curie.u-psud.fr.
Published, JBC Papers in Press, May 11, 2001, DOI 10.1074/jbc.M101812200
2
J. B. Sibarita and J. R. De Mey, manuscript in preparation.
 |
ABBREVIATIONS |
The abbreviations used are:
NR, neural retina;
RPE, retinal pigmented epithelium;
b-HLH-LZ, basic helix-loop-helix
leucine zipper domain;
FGF, fibroblast growth factor;
GST, glutathione S-transferase;
BHK, baby hamster kidney;
CAT, chloramphenicol acetyltransferase;
PBS, phosphate-buffered saline;
EGFP, enhanced green fluorescent protein;
Pipes, 1,4-piperazinediethanesulfonic acid.
 |
REFERENCES |
| 1.
|
Agata, K.,
Kobayashi, H.,
Itoh, Y.,
Mochii, M.,
Sawada, K.,
and Eguchi, G.
(1993)
Development
118,
1025-1030
|
| 2.
|
Park, C. M.,
and Hollenberg, M. J.
(1989)
Dev. Biol.
134,
201-205
|
| 3.
|
Pittack, C.,
Jones, M.,
and Reh, T. A.
(1991)
Development
113,
577-588
|
| 4.
|
Okada, T. S.
(1980)
in
Current Topics in Developmental Biology
(Moscona, A. A.
, and Monroy, A., eds)
, pp. 349-380, Academic Press, New York
|
| 5.
|
Turque, N.,
Denhez, F.,
Martin, P.,
Planque, N.,
Bailly, M.,
Begue, A.,
Stehelin, D.,
and Saule, S.
(1996)
EMBO. J.
15,
3338-3350
|
| 6.
|
Chow, R. L.,
Altmann, C. R.,
Lang, A. R.,
and Hemmati-Brivanlou, A.
(1999)
Development
126,
4213-4222
|
| 7.
|
Martin, P.,
Carriere, C.,
Dozier, C.,
Quatannens, B.,
Mirabel, M. A.,
Vandenbunder, B.,
Stehelin, D.,
and Saule, S.
(1992)
Oncogene
7,
1721-1728
|
| 8.
|
Carriere, C.,
Plaza, S.,
Caboche, J.,
Dozier, C.,
Bailly, M.,
Martin, P.,
and Saule, S.
(1995)
Cell Growth Differ.
6,
1531-1540
|
| 9.
|
Carriere, C.,
Plaza, S.,
Martin, P.,
Quatannens, B.,
Bailly, M.,
Stehelin, D.,
and Saule, S.
(1993)
Mol. Cell Biol
13,
7257-7266
|
| 10.
|
Callaerts, P.,
Halder, G.,
and Gehring, W. J.
(1997)
Annu. Rev. Neurosci.
20,
483-532
|
| 11.
|
Glaser, T.,
Walton, D.,
Cai, J.,
Epstein, J.,
Jepeal, L.,
and Maas, R. L.
(1995)
in
Molecular Genetics of Ocular Disease
(Wiggs, J., ed)
, pp. 55-81, Wiley, New York
|
| 12.
|
Hill, R. E.,
Favor, J.,
Hogan, B.,
Ton, C. C.,
Saunders, G.,
Hanson, I.,
Prosser, J.,
Jordan, T.,
Hastie, N,
and Heyningen, V. V.
(1991)
Nature
354,
522-525
|
| 13.
|
Schedl, A.,
Ross, A.,
Lee, M.,
Engelkamp, D.,
Rashbass, P.,
van Heyningen, V.,
and Hastie, N. D.
(1996)
Cell
86,
71-82
|
| 14.
|
Hodgkinson, C. A.,
Moore, K. J.,
Nakayama, A.,
Steingrimsson, E.,
Copeland, N. G,
Jenkins, N. A.,
and Arnheiter, H.
(1993)
Cell
74,
395-404
|
| 15.
|
Tachibana, M.,
Perez-Jurado, L. A.,
Nakayama, A.,
Hodgkinson, C. A.,
Li, X.,
Schneider, M.,
Miki, T.,
Fex, J.,
Francke, U.,
and Arnheiter, H.
(1994)
Hum. Mol. Genet.
3,
553-557
|
| 16.
|
Tassabehji, M.,
Newton, V. E.,
and Read, A. P.
(1994)
Nat. Genet.
8,
251-255
|
| 17.
|
Boissy, R. E.,
Boissy, Y. L.,
Krakowsky, J. M.,
Lamoreux, M. L.,
Lingrel, J. B.,
and Nordlund, J. J.
(1993)
J. Submicrosc. Cytol. Pathol.
25,
319-332
|
| 18.
|
Nakayama, A.,
Nguyen, M. T.,
Chen, C. C.,
Opdecamp, K.,
Hodgkinson, C. A.,
and Arnheiter, H.
(1998)
Mech. Dev.
70,
155-166
|
| 19.
|
Bumsted, K.,
and Barnstable, C. J.
(2000)
Investig. Ophthalmol. Vis. Sci.
41,
903-908
|
| 20.
|
Mochii, M.,
Ono, T.,
Matsubara, Y.,
and Eguchi, G.
(1998)
Dev. Biol.
(196),
145-159
|
| 21.
|
Planque, N.,
Turque, N.,
Opdecamp, K.,
Bailly, M.,
Martin, P.,
and Saule, S.
(1999)
Cell Growth Differ.
10,
525-536
|
| 22.
|
Bentley, N. J.,
Eisen, T.,
and Goding, C. R.
(1994)
Mol. Cell. Biol.
14,
7996-8006
|
| 23.
|
Yasumoto, K.,
Yokoyama, K.,
Shibata, K.,
Tomita, Y.,
and Shibahara, S.
(1994)
Mol. Cell. Biol.
14,
8058-8070
|
| 24.
|
Yavuzer, U.,
Keenan, E.,
Lowings, P.,
Vachtenheim, J.,
Currie, G.,
and Goding, C. R
(1995)
Oncogene
10,
123-134
|
| 25.
|
Aksan, I.,
and Goding, C. R.
(1998)
Mol. Cell. Biol.
18,
6930-6938
|
| 26.
|
Wakamatsu, Y.,
and Weston, J. A.
(1997)
Development
124,
3449-3460
|
| 27.
|
Plaza, S.,
Langlois, M. C.,
Turque, N.,
LeCornet, S.,
Bailly, M.,
Begue, A.,
Quatannens, B.,
Dozier, C.,
and Saule, S.
(1997)
Cell. Growth Differ.
8,
1115-1125
|
| 28.
|
Ritz-Laser, B.,
Estreicher, A.,
Klages, N.,
Saule, S.,
and Philippe, J.
(1999)
J. Biol. Chem.
274,
4124-4132
|
| 29.
|
Mikkola, I.,
Bruun, J. A.,
Holm, T.,
and Johansen, T.
(2000)
J. Biol. Chem.
276,
4109-4118
|
| 30.
|
Hussain, M. A.,
and Habener, J. F.
(1999)
J. Biol. Chem.
274,
28950-28957
|
| 31.
|
Cvekl, A.,
Kashanchi, F.,
Brady, J. N.,
and Piatigorsky, J.
(1999)
Investig. Ophthalmol. Vis. Sci.
40,
1343-1350
|
| 32.
|
Torres, M.,
Gomez-Pardo, E.,
and Gruss, P.
(1996)
Development
122,
3381-3391
|
| 33.
|
Sato, S.,
Roberts, K.,
Gambino, G.,
Cook, A.,
Kouzarides, T.,
and Goding, C. R.
(1997)
Oncogene
14,
3083-3092
|
| 34.
|
Takebayashi, K.,
Chida, K.,
Tsukamoto, I.,
Morii, E.,
Munakata, H.,
Arnheiter, H.,
Kuroki, T.,
Kitamura, Y.,
and Nomura, S.
(1996)
Mol. Cell. Biol.
16,
1203-1211
|
| 35.
|
Lam, P. Y.,
Sublett, J. E.,
Hollenbach, A. D.,
and Roussel, M. F.
(1999)
Mol. Cell. Biol.
19,
594-601
|
| 36.
|
Plaza, S.,
Dozier, C.,
and Saule, S.
(1993)
Cell. Growth Differ.
4,
1041-1050
|
| 37.
|
Bertolotto, C.,
Bille, K.,
Ortonne, J. P.,
and Ballotti, R.
(1996)
J. Cell Biol.
134,
747-755
|
| 38.
|
Klempnauer, K.-H.,
Arnold, H.,
and Biedenkapp, H.
(1989)
Genes Dev.
3,
1582-1589
|
| 39.
|
Fitzsimmons, D.,
Hodsdon, W.,
Wheat, W.,
Maira, S. M.,
Wasylyk, B.,
and Hagman, J.
(1996)
Genes Dev.
10,
2198-2211
|
| 40.
|
Xu, H. E.,
Rould, M. A.,
Xu, W.,
Epstein, J. A,
Maas, R. L.,
and Pabo, C. O.
(1999)
Genes Dev.
13,
1263-1275
|
| 41.
|
Epstein, J.,
Cai, J.,
Glaser, T.,
Jepeal, L.,
and Maas, R.
(1994)
J. Biol. Chem.
269,
8355-8361
|
| 42.
|
Hemesath, T. J.,
Steingrimsson, E.,
McGill, G.,
Hansen, M. J.,
Vaught, J.,
Hodgkinson, C. A.,
Arnheiter, H.,
Copeland, N. G.,
Jenkins, N. A.,
and Fisher, D. E.
(1994)
Genes Dev.
8,
2770-2780
|
| 43.
|
Watanabe, A.,
Takeda, K.,
Ploplis, B.,
and Tachibana, M.
(1998)
Nat. Genet.
18,
283-286
|
| 44.
|
Potterf, S. B.,
Furumura, M.,
Dunn, K. J.,
Arnheiter, H.,
and Pavan, W. J.
(2000)
Hum. Genet.
107,
1-6
|
| 45.
|
Epstein, J. A.,
Glaser, T.,
Cai, J.,
Jepeal, L.,
Walton, D. S.,
and Maas, R. L.
(1994)
Genes Dev
8,
2022-2034
|
| 46.
|
Goulding, M. D.,
Chalepakis, G.,
Deutsch, U.,
Erselius, J. R.,
and Gruss, P.
(1991)
EMBO J.
10,
1135-1147
|
| 47.
|
Singh, S.,
Stellrecht, C. M.,
Tang, H. K.,
and Saunders, G. F.
(2000)
J. Biol. Chem.
275,
17306-17313
|
| 48.
|
Singh, S.,
Chao, L. Y.,
Mishra, R.,
Davies, J.,
and Saunders, G. F.
(2001)
Hum. Mol. Genet.
10,
911-918
|
| 49.
|
Roberts, E. C.,
Deed, R. W.,
Inoue, T.,
Norton, J. D.,
and Sharrocks, A. D.
(2001)
Mol. Cell. Biol.
15,
524-533
|
| 50.
|
Knoepfler, P. S.,
Bergstrom, D. A.,
Uetsuki, T.,
Dac-Korytko, I.,
Sun, Y. H.,
Wright, W. E.,
Tapscott, S. J.,
and Kamps, M. P.
(1999)
Nucleic Acids Res.
27,
3752-3761
|
| 51.
|
Poulin, G.,
Lebel, M.,
Chamberland, M.,
Paradis, F. W.,
and Drouin, J.
(2000)
Mol. Cell. Biol
20,
4826-4837
|
| 52.
|
Ohneda, K.,
Mirmira, R. G.,
Wang, J.,
Johnson, J. D.,
and German, M. S.
(2000)
Mol. Cell. Biol
20,
900-911
|
| 53.
|
Nguyen, M.,
and Arnheiter, H.
(2000)
Development
127,
3581-3591
|
| 54.
|
Macdonald, R.,
Barth, K. A.,
Xu, Q.,
Holder, N.,
Mikkola, I.,
and Wilson, S. W.
(1995)
Development
121,
3267-3278
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
R. Zaccarini, F. P. Cordelieres, P. Martin, and S. Saule
PAX6 P46 Binds Chromosomes in the Pericentromeric Region and Induces a Mitosis Defect When Overexpressed
Invest. Ophthalmol. Vis. Sci.,
December 1, 2007;
48(12):
5408 - 5419.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Grinchuk, Z. Kozmik, X. Wu, and S. Tomarev
The Optimedin Gene Is a Downstream Target of Pax6
J. Biol. Chem.,
October 21, 2005;
280(42):
35228 - 35237.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-A. Bruun, E. I. S. Thomassen, K. Kristiansen, G. Tylden, T. Holm, I. Mikkola, G. Bjorkoy, and T. Johansen
The third helix of the homeodomain of paired class homeodomain proteins acts as a recognition helix both for DNA and protein interactions
Nucleic Acids Res.,
May 10, 2005;
33(8):
2661 - 2675.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Lin, A. J. Gerth, and S. L. Peng
Active Inhibition of Plasma Cell Development in Resting B Cells by Microphthalmia-associated Transcription Factor
J. Exp. Med.,
November 8, 2004;
(2004)
jem.20040612.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Leconte, L. Lecoin, P. Martin, and S. Saule
Pax6 Interacts with cVax and Tbx5 to Establish the Dorsoventral Boundary of the Developing Eye
J. Biol. Chem.,
November 5, 2004;
279(45):
47272 - 47277.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Zaniolo, S. Leclerc, A. Cvekl, L. Vallieres, R. Bazin, K. Larouche, and S. L. Guerin
Expression of the {alpha}4 Integrin Subunit Gene Promoter Is Modulated by the Transcription Factor Pax-6 in Corneal Epithelial Cells
Invest. Ophthalmol. Vis. Sci.,
June 1, 2004;
45(6):
1692 - 1704.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. H. Hallsson, B. S. Haflidadottir, C. Stivers, W. Odenwald, H. Arnheiter, F. Pignoni, and E. Steingrimsson
The Basic Helix-Loop-Helix Leucine Zipper Transcription Factor Mitf Is Conserved in Drosophila and Functions in Eye Development
Genetics,
May 1, 2004;
167(1):
233 - 241.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Rodrigo, P. Bovolenta, B. S. Mankoo, and K. Imai
Meox Homeodomain Proteins Are Required for Bapx1 Expression in the Sclerotome and Activate Its Transcription by Direct Binding to Its Promoter
Mol. Cell. Biol.,
April 1, 2004;
24(7):
2757 - 2766.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. R. Martinez-Morales, V. Dolez, I. Rodrigo, R. Zaccarini, L. Leconte, P. Bovolenta, and S. Saule
OTX2 Activates the Molecular Network Underlying Retina Pigment Epithelium Differentiation
J. Biol. Chem.,
June 6, 2003;
278(24):
21721 - 21731.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. K. Chauhan, N. A. Reed, W. Zhang, M. K. Duncan, M. W. Kilimann, and A. Cvekl
Identification of Genes Downstream of Pax6 in the Mouse Lens Using cDNA Microarrays
J. Biol. Chem.,
March 22, 2002;
277(13):
11539 - 11548.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Planque, L. Leconte, F. M. Coquelle, S. Benkhelifa, P. Martin, M.-P. Felder-Schmittbuhl, and S. Saule
Interaction of Maf Transcription Factors with Pax-6 Results in Synergistic Activation of the Glucagon Promoter
J. Biol. Chem.,
September 14, 2001;
276(38):
35751 - 35760.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|